TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 31356452

Group type: EXPERIMENTAL
Intervention: Kangaroo care (KC) and water
Number of subjects: 242

Group type: EXPERIMENTAL
Intervention: Kangaroo care (KC) and 24% sucrose
Number of subjects: 242

Group type: COMPARATOR
Intervention: 24% sucrose
Number of subjects: 242
Study: 29937255

Group type: EXPERIMENTAL
Intervention: Tailored implementation strategies
Number of subjects: 39

Group type: COMPARATOR
Intervention: Standardized implementation strategies
Number of subjects: 39
Study: 27373387

Group type: EXPERIMENTAL
Intervention: Intraoperative aberrometry measurements (Ocular Response Analyzer with Verifeye)
Number of subjects: 130

Group type: COMPARATOR
Intervention: Standard preoperative biometry and toric IOL calculator with inked axis marking
Number of subjects: 130
Study: 24953914

Group type: EXPERIMENTAL
Intervention: N-acetylcysteine nebulized therapy
Number of subjects: 100

Group type: COMPARATOR
Intervention: Salbutamol nebulized aerosol
Number of subjects: 100
Study: 21873370

Group type: EXPERIMENTAL
Intervention: Intraoperative goal-directed fluid therapy (GDT) with oesophageal Doppler monitoring (ODM)
Number of subjects: 179

Group type: EXPERIMENTAL
Intervention: Intraoperative goal-directed fluid therapy (GDT)
Number of subjects: 179

Group type: COMPARATOR
Intervention: Standard fluid regimen without ODM-guided intraoperative GDT
Number of subjects: 179
Study: 20067958

Group type: EXPERIMENTAL
Intervention: Lacosamide 400 mg/day
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Lacosamide 600 mg/day
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 18700304

Group type: EXPERIMENTAL
Intervention: Cefepime and Amikacin FDC (2.5g b.i.d)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Cefepime alone (2.0g b.i.d)
Number of subjects: 200
Study: 15616893

Group type: EXPERIMENTAL
Intervention: Vitamin K2 (15 mg per day) in addition to GC (group B)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Glucocorticoids alone (group A)
Number of subjects: 20
Study: 12777950

Group type: EXPERIMENTAL
Intervention: Superoxide dismutase
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Insulin treatment adjustment
Number of subjects: 24

Group type: COMPARATOR
Intervention: NG‐monomethyl‐l‐arginine
Number of subjects: 24

Group type: COMPARATOR
Intervention: Methacholine
Number of subjects: 24

Group type: COMPARATOR
Intervention: Nitroprusside
Number of subjects: 24
Study: 10680418

Group type: EXPERIMENTAL
Intervention: Fluoracaine
Number of subjects: 30

Group type: COMPARATOR
Intervention: Fluorox
Number of subjects: 30
Study: 8723170

Group type: EXPERIMENTAL
Intervention: Cilazapril 5 mg daily (n = 9)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Hydrochlorothiazide 25 mg daily (n = 8)
Number of subjects: 17
Study: 1314309

Group type: EXPERIMENTAL
Intervention: Synovial cell sarcoma
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Fibrosarcoma
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Malignant fibrous histiocytoma
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Malignant neurogenic tumors
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Tumors of the trunk
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Lower extremity tumors
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Upper extremity tumors
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Stage I tumors
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Stage II tumors
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Stage III tumors
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Stage IV tumors
Number of subjects: 75
Study: 3892993

Group type: EXPERIMENTAL
Intervention: ALB (80 g albumin on the day of operation and 20 g for the following 3 days)
Number of subjects: 26

Group type: COMPARATOR
Intervention: NON-ALB (no extra albumin)
Number of subjects: 26
Study: 31553725

Group type: EXPERIMENTAL
Intervention: ConTxt only (SMS intervention)
Number of subjects: 298

Group type: EXPERIMENTAL
Intervention: ConTxt plus health-coaching calls
Number of subjects: 298

Group type: COMPARATOR
Intervention: Control group (standard print materials)
Number of subjects: 298

Group type: EXPERIMENTAL
Intervention: ConTxt plus health-coaching calls vs Control group
Number of subjects: 298

Group type: EXPERIMENTAL
Intervention: ConTxt only vs Control group
Number of subjects: 298

Group type: EXPERIMENTAL
Intervention: ConTxt plus health-coaching calls vs ConTxt only
Number of subjects: 298

Group type: EXPERIMENTAL
Intervention: Spanish speakers vs English speakers in ConTxt plus health-coaching calls
Number of subjects: 298
Study: 27743840

Group type: EXPERIMENTAL
Intervention: PAVeD
Number of subjects: 203

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 203
Study: 26181014

Group type: EXPERIMENTAL
Intervention: Erlotinib treatment
Number of subjects: 97
Study: 23950057

Group type: EXPERIMENTAL
Intervention: Oxytocin
Number of subjects: 13

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13
Study: 21715107

Group type: EXPERIMENTAL
Intervention: memantine 15 mg bid
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: memantine 30 mg bid
Number of subjects: 112

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 112
Study: 19564368

Group type: COMPARATOR
Intervention: 320 mg gemifloxacin as an oral tablet without probenecid
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: 320 mg gemifloxacin as an oral tablet with 4.5 g probenecid divided in eight oral doses
Number of subjects: 17
Study: 16219709

Group type: EXPERIMENTAL
Intervention: DAS28 remission criterion (cut off level: 2.6)
Number of subjects: 155

Group type: COMPARATOR
Intervention: DAS remission criterion (cut off level: 1.6)
Number of subjects: 155

Group type: EXPERIMENTAL
Intervention: Total Joint Count (TJC) >0
Number of subjects: 155

Group type: EXPERIMENTAL
Intervention: Swollen Joint Count >0
Number of subjects: 155

Group type: EXPERIMENTAL
Intervention: Lower extremity joint involvement
Number of subjects: 155
Study: 15518674

Group type: EXPERIMENTAL
Intervention: Psychological intervention by a qualified therapist plus care as usual by a general practitioner (GP)
Number of subjects: 98

Group type: COMPARATOR
Intervention: Care as usual only
Number of subjects: 98
Study: 11701572

Group type: EXPERIMENTAL
Intervention: Intensive case management (caseload 10‐15 per case manager) for two years
Number of subjects: 708

Group type: COMPARATOR
Intervention: Standard case management (30‐35 per case manager)
Number of subjects: 708
Study: 9385499

Group type: EXPERIMENTAL
Intervention: Diskhaler inhaler
Number of subjects: 213

Group type: EXPERIMENTAL
Intervention: Diskus inhaler
Number of subjects: 213

Group type: EXPERIMENTAL
Intervention: Preference
Number of subjects: 213
Study: 7944875

Group type: EXPERIMENTAL
Intervention: Tryptophan depletion
Number of subjects: 43

Group type: COMPARATOR
Intervention: Control test
Number of subjects: 43
Study: 3555569

Group type: EXPERIMENTAL
Intervention: nalbuphine 10 mg
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: nalbuphine 20 mg
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: pethidine 100 mg
Number of subjects: 80

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 80
Study: 2317416

Group type: EXPERIMENTAL
Intervention: Nitrous oxide
Number of subjects: 40

Group type: COMPARATOR
Intervention: Air
Number of subjects: 40
Study: 31635258

Group type: EXPERIMENTAL
Intervention: Breakfast consumers
Number of subjects: 802

Group type: EXPERIMENTAL
Intervention: Breakfast consumption
Number of subjects: 802

Group type: COMPARATOR
Intervention: Physical activity
Number of subjects: 802
Study: 29045207

Group type: EXPERIMENTAL
Intervention: 5 mg of tofacitinib administered orally twice daily
Number of subjects: 395

Group type: EXPERIMENTAL
Intervention: 10 mg of tofacitinib administered orally twice daily
Number of subjects: 395

Group type: COMPARATOR
Intervention: Placebo (with a switch to 5 mg of tofacitinib at 3 months)
Number of subjects: 395
Study: 24865592

Group type: EXPERIMENTAL
Intervention: Dexamethasone (8 mg)
Number of subjects: 616
Study: 22990950

Group type: EXPERIMENTAL
Intervention: Multimodal shoulder injection
Number of subjects: 70

Group type: COMPARATOR
Intervention: IV PCA
Number of subjects: 70
Study: 21899843

Group type: EXPERIMENTAL
Intervention: Atorvastatin or pitavastatin treatment
Number of subjects: 307
Study: 19391543

Group type: EXPERIMENTAL
Intervention: Acupuncture and moxibustion literature analysis
Number of subjects: 4041
Study: 16481597

Group type: EXPERIMENTAL
Intervention: Creatine 10 g/day
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Minocycline 200 mg/day
Number of subjects: 200

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 200
Study: 12762352

Group type: EXPERIMENTAL
Intervention: Chlorine inhalation (1.0 parts per million for 15 min)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Nasal allergen challenge
Number of subjects: 16

Group type: COMPARATOR
Intervention: Filtered air (control)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Nasal lavage (post-exposure measurement)
Number of subjects: 16
Study: 11487162

Group type: EXPERIMENTAL
Intervention: Geristore
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Super‐EBA
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: ProRoot
Number of subjects: 100

Group type: COMPARATOR
Intervention: Positive control (open root-end cavities)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Negative control (sticky wax and nail polish)
Number of subjects: 100
Study: 9662320

Group type: EXPERIMENTAL
Intervention: Viewing a movie through video eyeglasses
Number of subjects: 89

Group type: COMPARATOR
Intervention: Active play (singing, blowing bubbles)
Number of subjects: 89

Group type: COMPARATOR
Intervention: Passive play (being read to)
Number of subjects: 89
Study: 8151150

Group type: EXPERIMENTAL
Intervention: Aciclovir granules (40% w/w aciclovir) at a dose of 20 mg/kg four times daily for five to seven days
Number of subjects: 104

Group type: COMPARATOR
Intervention: Conventional symptomatic therapy
Number of subjects: 104
Study: 3061369

Group type: EXPERIMENTAL
Intervention: levamisole
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: penicillamine
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: azathioprine
Number of subjects: 36

Group type: COMPARATOR
Intervention: Control group (10 age matched controls)
Number of subjects: 36
Study: 31916648

Group type: EXPERIMENTAL
Intervention: quadruple‐therapy with 2 g/day N. sativa
Number of subjects: 51

Group type: COMPARATOR
Intervention: quadruple‐therapy with 2 g/day placebo
Number of subjects: 51
Study: 30173153

Group type: EXPERIMENTAL
Intervention: Adalimumab (ADA) with Methotrexate (MTX) 20 mg/week
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Adalimumab (ADA) with Methotrexate (MTX) 7.5 mg/week
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (nonobese patients)
Number of subjects: 0
Study: 26361776

Group type: EXPERIMENTAL
Intervention: ExoSeal® vascular closure device (VCD)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Manual compression (MC)
Number of subjects: 48
Study: 25394429

Group type: EXPERIMENTAL
Intervention: 20% human albumin
Number of subjects: 80

Group type: COMPARATOR
Intervention: 0.9% normal saline alone
Number of subjects: 80
Study: 23368897

Group type: EXPERIMENTAL
Intervention: Fluticasone/formoterol combination therapy (100/10 μg b.i.d. or 250/10 μg b.i.d.)
Number of subjects: 210

Group type: COMPARATOR
Intervention: Fluticasone + formoterol (100 μg + 12 μg b.i.d. or 250 μg + 12 μg b.i.d.)
Number of subjects: 210

Group type: EXPERIMENTAL
Intervention: Fluticasone/formoterol combination therapy
Number of subjects: 210

Group type: COMPARATOR
Intervention: Fluticasone + formoterol
Number of subjects: 210
Study: 20206776

Group type: EXPERIMENTAL
Intervention: Apixaban 2.5 mg twice daily
Number of subjects: 3057

Group type: COMPARATOR
Intervention: Enoxaparin 40 mg once daily
Number of subjects: 3057
Study: 18853878

Group type: EXPERIMENTAL
Intervention: Debridement three times during the first postoperative week
Number of subjects: 90

Group type: COMPARATOR
Intervention: Debridement once on the 7th postoperative day (Control)
Number of subjects: 90
Study: 17111990

Group type: EXPERIMENTAL
Intervention: Systematically implemented psychotherapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Common aspects of all psychotherapies
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Suitability and competence of the psychotherapist
Number of subjects: 0
Study: 12725765

Group type: EXPERIMENTAL
Intervention: Optimized voxel-based morphometry (VBM) method
Number of subjects: 0
Study: 11323554

Group type: EXPERIMENTAL
Intervention: Creatine (20 g.d‐1 for 5 days)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study: 9195406

Group type: EXPERIMENTAL
Intervention: Interferon-alpha therapy (6-9 MU; six times weekly for 2 weeks followed by thrice weekly for 22 additional weeks)
Number of subjects: 43
Study: 8186869

Group type: COMPARATOR
Intervention: Preoperative radiation therapy (20 Gy in four 5 Gy fractions)
Number of subjects: 293

Group type: EXPERIMENTAL
Intervention: Preoperative radiation therapy (20 Gy) plus local microwave hyperthermia
Number of subjects: 293

Group type: EXPERIMENTAL
Intervention: Radiation therapy
Number of subjects: 293

Group type: EXPERIMENTAL
Intervention: Radiation therapy with hyperthermia
Number of subjects: 293
Study: 3473193

Group type: EXPERIMENTAL
Intervention: Nalbuphine
Number of subjects: 40

Group type: COMPARATOR
Intervention: Meperidine
Number of subjects: 40
Study: 30964381

Group type: EXPERIMENTAL
Intervention: Roflumilast for 4 weeks
Number of subjects: 9

Group type: COMPARATOR
Intervention: Placebo for 4 weeks
Number of subjects: 9
Study: 27135478

Group type: EXPERIMENTAL
Intervention: Aqua Cycling (AC)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Passive Recovery (P)
Number of subjects: 20
Study: 25523718

Group type: EXPERIMENTAL
Intervention: High-dose trivalent inactivated influenza vaccine (TIV) - 60 μg
Number of subjects: 38

Group type: COMPARATOR
Intervention: Standard-dose trivalent inactivated influenza vaccine (TIV) - 15 μg
Number of subjects: 38
Study: 23659825

Group type: EXPERIMENTAL
Intervention: Sevoflurane-sufentanil combined anesthesia with intraoperative wake-up test
Number of subjects: 30

Group type: COMPARATOR
Intervention: Sevoflurane-sufentanil combined anesthesia without intraoperative wake-up test
Number of subjects: 30
Study: 21850510

Group type: EXPERIMENTAL
Intervention: Retropubic operation
Number of subjects: 267

Group type: EXPERIMENTAL
Intervention: Transobturator operation
Number of subjects: 267

Group type: EXPERIMENTAL
Intervention: Mid-urethral sling procedures (overall intervention)
Number of subjects: 267
Study: 19571750

Group type: EXPERIMENTAL
Intervention: Mexiletine in nondystrophic myotonias
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Flecainide
Number of subjects: 0
Study: 17713344

Group type: EXPERIMENTAL
Intervention: Saliva from 7 subjects (enamel)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Saliva from 6 subjects (dentine)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Saliva from 1 subject
Number of subjects: 14

Group type: COMPARATOR
Intervention: Control (water)
Number of subjects: 14
Study: 14982697

Group type: EXPERIMENTAL
Intervention: Ethanol (0.5 g/kg)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Mecamylamine (10 mg oral)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Nicotine (vs. denicotinized cigarette smoke)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Placebo (vs. ethanol)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Placebo (vs. mecamylamine)
Number of subjects: 48
Study: 11420874

Group type: EXPERIMENTAL
Intervention: Daily hemodialysis (DHD = 6 x 2 h/week)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Standard hemodialysis (SHD = 3 x 4 h/week)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Control subjects
Number of subjects: 10
Study: 9665186

Group type: EXPERIMENTAL
Intervention: Early intensification block
Number of subjects: 0

Group type: COMPARATOR
Intervention: Late intensification block
Number of subjects: 0
Study: 8073910

Group type: EXPERIMENTAL
Intervention: Thymoxamine (alpha adrenergic receptor antagonist)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Methoxamine (alpha-1 adrenergic receptor agonist)
Number of subjects: 36
Study: 2673620

Group type: EXPERIMENTAL
Intervention: Adenosine infusion (0.07 mg/kg/min)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Nicotine gum chewing
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Nicotine during adenosine infusion
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Combined administration of nicotine and adenosine
Number of subjects: 10
Study: 239109

Group type: EXPERIMENTAL
Intervention: 0.58M (7%) THAM over 30 seconds
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: molar bicarbonate over 30 seconds
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: molar bicarbonate over 2 minutes
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: molar bicarbonate over 5 minutes
Number of subjects: 19
Study: 30378278

Group type: EXPERIMENTAL
Intervention: Three-dimensional (3D) quiz application
Number of subjects: 0

Group type: COMPARATOR
Intervention: Traditional teaching with extracted/model teeth
Number of subjects: 0
Study: 28236862

Group type: EXPERIMENTAL
Intervention: 2mgkg‐1 sugammadex (Group S)
Number of subjects: 98

Group type: COMPARATOR
Intervention: 50μgkg‐1 neostigmine plus 0.2mgkg‐1 atropine (Group N)
Number of subjects: 98

Group type: COMPARATOR
Intervention: Group N
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: Group S
Number of subjects: 98
Study: 24787302

Group type: EXPERIMENTAL
Intervention: Double-sugar-tong splint (DSTS)
Number of subjects: 71

Group type: COMPARATOR
Intervention: Long-arm cast (LAC)
Number of subjects: 71
Study: 23186950

Group type: EXPERIMENTAL
Intervention: Sitagliptin 100 mg/day
Number of subjects: 141

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 141
Study: 22145828

Group type: EXPERIMENTAL
Intervention: High intensity intervention (30 minutes of individualized cognitive-behavioral intervention and a self-help manual)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Low intensity intervention (brief advice for 5 minutes and a short leaflet)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Follow-up at six months postpartum
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Infants' birth weight, gestational age, and health-related complications during pregnancy
Number of subjects: 0
Study: 19249415

Group type: EXPERIMENTAL
Intervention: Cardiac resynchronization therapy (CRT)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 17250777

Group type: EXPERIMENTAL
Intervention: 50 mg imipramine
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 15236439

Group type: EXPERIMENTAL
Intervention: Baclofen (Polpharma)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Lioresal (Novartis)
Number of subjects: 18
Study: 11210404

Group type: EXPERIMENTAL
Intervention: Azithromycin 1200 mg/day (changed to 600 mg/day) for Days 8 to 21 with zidovudine 100 mg, five times/day.
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Azithromycin 1200 mg/day for Days 8 to 21 with dideoxyinosine 200 mg twice daily.
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo equivalent to azithromycin for Days 8 to 21 with dideoxyinosine 200 mg twice daily.
Number of subjects: 12
Study: 9624643

Group type: EXPERIMENTAL
Intervention: Glutamine supplementation
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study: 8986931

Group type: EXPERIMENTAL
Intervention: Normal sodium diet
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Sodium-restricted diet
Number of subjects: 6

Group type: COMPARATOR
Intervention: Non-sodium-sensitive essential hypertension (Control group)
Number of subjects: 6
Study: 1981014

Group type: EXPERIMENTAL
Intervention: Chemotherapy with estrogenic recruitment (low doses of diethylstilbesterol)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Conventional polychemotherapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Recombinant human growth hormone
Number of subjects: 0
Study: 7033568

Group type: EXPERIMENTAL
Intervention: Submucosal tunnel technique for prevention of reflux
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Imipramine hydrochloride
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 31618672

Group type: EXPERIMENTAL
Intervention: Extinguished cue during training
Number of subjects: 0

Group type: COMPARATOR
Intervention: Non-extinguished cue
Number of subjects: 0
Study: 27798397

Group type: EXPERIMENTAL
Intervention: PP‐ACT
Number of subjects: 104

Group type: COMPARATOR
Intervention: C‐ACT
Number of subjects: 104
Study: 25304836

Group type: EXPERIMENTAL
Intervention: Single dose antibiotic regimen (n = 103)
Number of subjects: 205

Group type: COMPARATOR
Intervention: Multidose antibiotic regimen (n = 102)
Number of subjects: 205
Study: 25359150

Group type: EXPERIMENTAL
Intervention: Pateclizumab 360 mg
Number of subjects: 214

Group type: EXPERIMENTAL
Intervention: Adalimumab 40 mg
Number of subjects: 214

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 214
Study: 22594649

Group type: EXPERIMENTAL
Intervention: KRTE only (KO)
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Acupuncture only (AO)
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: KRTE and acupuncture combined (KA)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Waiting list group (WL)
Number of subjects: 44
Study: 20413058

Group type: EXPERIMENTAL
Intervention: Once-daily ADPREM
Number of subjects: 38

Group type: COMPARATOR
Intervention: Twice-daily CRM
Number of subjects: 38
Study: 18614424

Group type: EXPERIMENTAL
Intervention: Sildenafil citrate (100 mg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Tadalafil (20 mg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Untreated controls
Number of subjects: 0
Study: 15749968

Group type: EXPERIMENTAL
Intervention: Going Places Program
Number of subjects: 1320
Study: 11918715

Group type: EXPERIMENTAL
Intervention: Interleukin-10 (10 microg per kg body weight; n = 7)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Placebo (n = 10)
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Interleukin-10
Number of subjects: 17

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17
Study: 10509984

Group type: EXPERIMENTAL
Intervention: Stentless xenograft (SX)
Number of subjects: 139

Group type: COMPARATOR
Intervention: Cryopreserved aortic or pulmonary homografts (HX)
Number of subjects: 139
Study: 8621019

Group type: EXPERIMENTAL
Intervention: Vanadyl sulfate (100 mg/day)
Number of subjects: 13

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13
Study: 1591738

Group type: EXPERIMENTAL
Intervention: Nimodipine (40 mg)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12